| Index | — | P/E | — | EPS (ttm) | -709.70 | Insider Own | 37.62% | Shs Outstand | 80.17M | Perf Week | -12.50% |
| Market Cap | 185.20M | Forward P/E | — | EPS next Y | -2.52 | Insider Trans | 0.00% | Shs Float | 453.37K | Perf Month | -40.62% |
| Enterprise Value | 158.51M | PEG | — | EPS next Q | -0.69 | Short Float | — | Perf Quarter | -73.96% | ||
| Income | -182.00M | P/S | — | EPS this Y | — | Short Ratio | 8.14 | Perf Half Y | -72.70% | ||
| Sales | 0.00 | P/B | 0.57 | EPS next Y | — | ROA | -48.34% | Short Interest | 3.85M | Perf YTD | -81.55% |
| Book/sh | 4.03 | P/C | 0.82 | EPS next 5Y | — | ROE | -46.90% | 52W High | 14.87 -84.29% | Perf Year | -80.75% |
| Cash/sh | 2.82 | P/FCF | — | EPS past 3/5Y | — | ROIC | -61.10% | 52W Low | 2.29 1.81% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 8.94% 7.50% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 0.26 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 4.69 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 20.10 | Recom | 2.00 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.69 | EPS Q/Q | 98.60% | SMA20 | -20.45% | Beta | 1.53 | Target Price | 19.00 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | — | SMA50 | -52.52% | Rel Volume | 1.06 | Prev Close | 2.31 |
| Employees | 88 | LT Debt/Eq | 0.01 | Earnings | Nov 11 | SMA200 | -71.44% | Avg Volume | 545.77K | Price | 2.34 |
| IPO Date | Aug 12, 2025 | Option/Short | No / Yes | EPS/Sales Surpr. | -24.81% — | Net Debt/EBITDA | — | Volume | 579,578 | Change | 1.15% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-09-26 | Reiterated | Stifel Nicolaus | $23 → $15 | |
| Sep-09-26 | Reiterated | Canaccord Genuity | Buy | $23 → $20 |
| Sep-09-26 | Reiterated | Raymond James | Outperform | $24 → $22 |
| May-11-26 | Initiated | Canaccord | Buy | $23 |
| Feb-10-26 | Initiated | Stifel | Buy | $23 |
| Jan-09-26 | Initiated | Raymond James | Outperform | $24 |
| Jan-08-26 | Reiterated | Morgan Stanley | $20 → $18 | |
| Dec-05-25 | Initiated | Morgan Stanley | Overweight | $20 |
| Sep-17-25 | Initiated | Leerink | Outperform | $25 |
| Sep-15-25 | Initiated | H.C | Buy |
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | |
|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | — | — | |
| Gross Profit | 0 | 0 | 0 | 0 | — | — | |
| Selling, General and Administrative Excl. Other | 36 | 25 | 8 | 8 | — | — | |
| Research and Development | 162 | 121 | 73 | 56 | — | — | |
| Other Operating Expense | 0 | 0 | 0 | 1 | — | — | |
| Operating Income | -198 | -146 | -81 | -65 | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | |
| Unusual Expense | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 17 | 12 | 7 | 0 | — | — | |
| Net Income Before Taxes | -182 | -134 | -74 | -65 | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | |
| Consolidated Net Income | -182 | -134 | -74 | -65 | — | — | |
| Net Income From Continuing Operations | -182 | -134 | -74 | -65 | — | — | |
| Net Income | -182 | -134 | -74 | -65 | — | — | |
| EPS (Recurring) | -1,232.82 | -4.30 | -5,756.41 | -0.00 | — | — | |
| EPS (Basic, Before Extraordinaries) | -1,232.82 | -4.30 | -5,756.41 | -0.00 | — | — | |
| EPS (Diluted) | -709.70 | -4.30 | -5,756.41 | -3.16 | — | — | |
| EBITDA | -194 | -145 | -81 | -65 | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | |
| Shares Outstanding | 0 | 31 | 0 | 20 | — | — | |
| Market Capitalization | — | 388 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Chen Bihua | Director, 10% Owner | Aug 11 '25 | Option Exercise | 0.00 | 4,172,126 | 417 | 4,681,126 | Aug 13 |
| Holman Albert A III | Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |
| McKenna Mark C. | Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |
| Schmid John P. | Former Director | Aug 11 '25 | Option Exercise | 0.00 | 30,000 | 0 | 30,000 | Aug 11 |